ZA200907753B - Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography - Google Patents
Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography Download PDFInfo
- Publication number
- ZA200907753B ZA200907753B ZA200907753A ZA200907753A ZA200907753B ZA 200907753 B ZA200907753 B ZA 200907753B ZA 200907753 A ZA200907753 A ZA 200907753A ZA 200907753 A ZA200907753 A ZA 200907753A ZA 200907753 B ZA200907753 B ZA 200907753B
- Authority
- ZA
- South Africa
- Prior art keywords
- ivabradine
- computed tomography
- coronary angiography
- diagnostic agent
- administration
- Prior art date
Links
- 229960003825 ivabradine Drugs 0.000 title claims description 20
- 238000002586 coronary angiography Methods 0.000 title claims description 13
- 238000002591 computed tomography Methods 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 11
- 239000000032 diagnostic agent Substances 0.000 title claims description 6
- 229940039227 diagnostic agent Drugs 0.000 title claims description 6
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 7
- 229940102223 injectable solution Drugs 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 description 24
- 229960000504 ivabradine hydrochloride Drugs 0.000 description 7
- 230000000284 resting effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000403635 Arses Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000004429 Calibre Substances 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- -1 colourants Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000193 iodinated contrast media Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0806225A FR2938194B1 (fr) | 2008-11-07 | 2008-11-07 | Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200907753B true ZA200907753B (en) | 2010-07-28 |
Family
ID=40677692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200907753A ZA200907753B (en) | 2008-11-07 | 2009-11-04 | Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography |
Country Status (44)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2579859T3 (pl) * | 2010-06-14 | 2015-12-31 | Ratiopharm Gmbh | Kompozycja stała zawierająca iwabradynę |
| CN106580873A (zh) * | 2016-11-08 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | 伊伐布雷定或其可药用盐口服溶液及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| JP4816083B2 (ja) | 2003-08-08 | 2011-11-16 | 小野薬品工業株式会社 | 短時間型β遮断薬を有効成分とする心拍数減少剤 |
| FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
| FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
-
2008
- 2008-11-07 FR FR0806225A patent/FR2938194B1/fr not_active Expired - Fee Related
-
2009
- 2009-10-27 UY UY0001032202A patent/UY32202A/es not_active Application Discontinuation
- 2009-10-27 PE PE2009001203A patent/PE20100744A1/es not_active Application Discontinuation
- 2009-10-27 SG SG200907132-5A patent/SG161186A1/en unknown
- 2009-10-29 MY MYPI20094554A patent/MY145991A/en unknown
- 2009-10-29 IL IL201815A patent/IL201815A/en not_active IP Right Cessation
- 2009-10-30 CO CO09123025A patent/CO6230160A1/es not_active Application Discontinuation
- 2009-10-31 SA SA109300653A patent/SA109300653B1/ar unknown
- 2009-11-02 MA MA32319A patent/MA31418B1/fr unknown
- 2009-11-02 AU AU2009235984A patent/AU2009235984B2/en not_active Ceased
- 2009-11-02 JO JO2009405A patent/JO2838B1/en active
- 2009-11-04 UA UAA200911196A patent/UA101612C2/uk unknown
- 2009-11-04 NI NI200900195A patent/NI200900195A/es unknown
- 2009-11-04 CR CR11094A patent/CR11094A/es unknown
- 2009-11-04 KR KR1020090105856A patent/KR101168484B1/ko active IP Right Grant
- 2009-11-04 SV SV2009003401A patent/SV2009003401A/es active IP Right Grant
- 2009-11-04 ZA ZA200907753A patent/ZA200907753B/en unknown
- 2009-11-05 NZ NZ580984A patent/NZ580984A/en not_active IP Right Cessation
- 2009-11-05 US US12/590,269 patent/US20100119459A1/en not_active Abandoned
- 2009-11-05 AP AP2009005035A patent/AP2635A/xx active
- 2009-11-05 GT GT200900288A patent/GT200900288A/es unknown
- 2009-11-05 EC EC2009009715A patent/ECSP099715A/es unknown
- 2009-11-05 CA CA2685303A patent/CA2685303C/fr not_active Expired - Fee Related
- 2009-11-05 CL CL2009002032A patent/CL2009002032A1/es unknown
- 2009-11-05 GE GEAP200911545A patent/GEP20135729B/en unknown
- 2009-11-06 ES ES09290841T patent/ES2370145T3/es active Active
- 2009-11-06 EA EA200901369A patent/EA017641B1/ru not_active IP Right Cessation
- 2009-11-06 ME MEP-2009-328A patent/ME00953B/me unknown
- 2009-11-06 TW TW098137810A patent/TWI426923B/zh not_active IP Right Cessation
- 2009-11-06 SI SI200930057T patent/SI2184065T1/sl unknown
- 2009-11-06 DK DK09290841.7T patent/DK2184065T3/da active
- 2009-11-06 EP EP09290841A patent/EP2184065B1/fr active Active
- 2009-11-06 RS RS20110378A patent/RS51948B/en unknown
- 2009-11-06 PA PA20098847801A patent/PA8847801A1/es unknown
- 2009-11-06 PL PL09290841T patent/PL2184065T3/pl unknown
- 2009-11-06 JP JP2009254783A patent/JP2010111673A/ja active Pending
- 2009-11-06 CN CN200910220828A patent/CN101732734A/zh active Pending
- 2009-11-06 MX MX2009012014A patent/MX2009012014A/es active IP Right Grant
- 2009-11-06 BR BRPI0904376-4A patent/BRPI0904376A2/pt not_active Application Discontinuation
- 2009-11-06 AT AT09290841T patent/ATE516806T1/de active
- 2009-11-06 WO PCT/FR2009/001282 patent/WO2010052394A1/fr active Application Filing
- 2009-11-06 AR ARP090104293A patent/AR074294A1/es unknown
-
2011
- 2011-09-22 HR HR20110684T patent/HRP20110684T1/hr unknown
- 2011-09-27 CY CY20111100927T patent/CY1112037T1/el unknown
-
2012
- 2012-11-02 JP JP2012242503A patent/JP6029935B2/ja active Active
-
2015
- 2015-10-21 JP JP2015206934A patent/JP2016040304A/ja active Pending
-
2016
- 2016-08-25 US US15/247,037 patent/US20160361444A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elliott et al. | Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage | |
| US20120184545A1 (en) | Heart-slowing drug containing short-acting beta-blocker as teh active ingredient | |
| Pichler et al. | Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography | |
| Kitagawa et al. | Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography | |
| AU2009235984B2 (en) | Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography | |
| JP7223692B2 (ja) | イメージング剤および使用の方法 | |
| Kido et al. | Radiation-Dose-Lowering Effects of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT)–A Prospective Multicenter Study– | |
| JP5648287B2 (ja) | 冠動脈の描出能改善剤 | |
| Yokohama et al. | Coronary endothelium-dependent and independent vasomotor responses in patients with hypertrophic cardiomyopathy | |
| IL305996A (en) | DC009 for the treatment of acute ischemic stroke |